scRNAseq of thyroid eye disease orbital fat demonstrates fibroblast thyroid hormone signaling and SPARC production

This study identifies SPARC as a promising biomarker for active thyroid eye disease by demonstrating its elevated expression in orbital fibroblasts, its correlation with disease severity and thyroid hormone levels, and its decline following the active phase of the condition.

The Gist

The Big Picture: A Garden Gone Wild

Imagine your eye socket (the orbit) is a garden. In a healthy person, this garden has just the right amount of soil (fat) and plants (fibroblasts) to keep the eyes sitting comfortably in their sockets.

In Thyroid Eye Disease (TED), something goes wrong. The garden starts to overgrow. The soil swells up, the plants grow wild, and the whole thing gets inflamed. This pushes the eyes forward, making them bulge, and can even threaten vision. This paper is a detective story about why this garden is going crazy and finding a new way to measure how bad the storm is.

The Investigation: Taking a "Snapshot" of the Garden

The researchers took tiny samples of this "garden" (orbital fat) from patients who needed surgery to relieve pressure. They didn't just look at the whole garden; they used a high-tech microscope called scRNAseq to take a snapshot of every single cell inside, reading their genetic "instruction manuals."

What they found:

1. The Workers (Fibroblasts): These are the cells responsible for building the garden's structure. In TED patients, these workers were hyperactive. They were listening to a specific set of instructions: "Build more!" and "Grow faster!"
2. The Radio Signals: The researchers discovered these workers were tuned into two main radio stations:
   • Thyroid Hormone Radio: Even though the workers weren't the thyroid gland, they had receivers for thyroid hormones. If the thyroid was sending out too much signal (hyperthyroidism), the garden workers got excited and started building too much.
   • Growth Factor Radio: They were also listening to signals like IGF-1, which tells cells to grow.
3. The Construction Material (SPARC): The most important discovery was that these overactive workers were churning out a specific building material called SPARC. Think of SPARC as the cement and mortar that holds the garden together. In TED, the workers were dumping out way too much cement, causing the garden to become hard, swollen, and fibrotic (scarred).

The Breakthrough: Finding the "Smoke Alarm"

For a long time, doctors have struggled to tell if a patient's TED is currently "active" (the storm is raging) or "quiet" (the storm has passed, but the damage remains).

The researchers asked: "If the garden workers are dumping so much cement (SPARC) inside the eye, does some of it leak out into the bloodstream?"

The Answer: Yes.
They tested the blood of many patients and found a clear pattern:

• Healthy people: Very low levels of SPARC.
• People with thyroid issues (but no eye disease): Slightly higher levels.
• People with active, severe TED: Very high levels of SPARC.

The Analogy: Think of SPARC in the blood like smoke from a fire.

• If you see smoke (high SPARC), you know the fire (active inflammation) is currently burning.
• If the smoke clears (SPARC levels drop), the fire is out, even if the charred wood (scarring) is still there.

The "Smoke Alarm" Works in Real Life

The researchers didn't just look at one group of people; they checked multiple groups from different countries and studies. The pattern held up every time.

• Correlation: The more severe the eye disease, the more "smoke" (SPARC) was in the blood.
• Time Travel: They watched patients over a year. When the patients started treatment and the disease went into remission, the SPARC levels in their blood dropped significantly. This proves SPARC is a dynamic marker—it goes up when the disease is active and down when it's healing.

Why This Matters

1. A New Tool for Doctors: Currently, doctors guess if a disease is active based on how the eyes look. This new test (measuring SPARC in blood) gives a concrete number. It's like having a thermometer for the inflammation.
2. The Thyroid Connection: The study confirmed that keeping thyroid hormone levels normal is crucial. If the "Thyroid Radio" signal is too loud, it keeps the garden workers building cement, making the disease worse.
3. Future Treatments: Since SPARC is the main "cement" causing the hardening, maybe in the future, we can develop drugs that specifically stop the production of SPARC, softening the garden and saving vision.

Summary

This paper is like finding the smoke detector for Thyroid Eye Disease. By studying the cells inside the eye, the researchers found that the disease is driven by thyroid signals causing cells to overproduce a cement-like protein called SPARC. They proved that this protein leaks into the blood, where it can be measured to tell doctors exactly how "active" the disease is, helping them treat patients faster and more effectively.

Technical Summary

1. Problem Statement

Thyroid Eye Disease (TED), an autoimmune condition often associated with Graves' disease, involves orbital inflammation, adipose tissue expansion, and extracellular matrix (ECM) deposition, leading to proptosis and potential blindness. Despite the known role of TSH receptor (TSHR) and IGF-1 receptor (IGF1R) signaling, there is a critical unmet need for:

• A deeper molecular understanding of how thyroid hormones and growth factors drive pathological processes in orbital fibroblasts.
• Reliable, non-invasive biomarkers to distinguish active TED from inactive disease or thyroid disease without orbital involvement.
• Clarification of the specific cell types and signaling pathways (beyond TSHR/IGF1R) driving fibrosis and inflammation in the orbit.

2. Methodology

The study employed a multi-modal approach combining single-cell transcriptomics, serum proteomics, and histology across multiple clinical cohorts.

• Single-Cell RNA Sequencing (scRNAseq):

  • Source: Orbital fat samples obtained from 4–5 patients undergoing orbital decompression surgery for TED.
  • Processing: Tissue was digested into single cells, processed using the 10x Genomics Single Cell 5' Reagent kit, and sequenced on an Illumina NextSeq.
  • Analysis: Data was processed using CellRanger, Seurat (v4.1.1), and Harmony for batch correction. Cell types were annotated using reference atlases (Azimuth, Fibroblast Atlas, Human Primary Cell Atlas).
  • Comparative Analysis: Freshly isolated TED fibroblasts were compared against published datasets of cultured TED fibroblasts (Kim et al.) and mesenchymal progenitors (Merrick et al.).

• Serum Biomarker Analysis:

  • Cohorts: Serum samples were analyzed from four distinct cohorts:
    1. CIRTED: Active moderate-to-severe TED (n=48).
    2. INDIGO: Active/new-onset Graves' disease (n=39).
    3. IDG: Longstanding Graves' disease and other thyroid disorders (n=31).
    4. Essen Cohort: Graves' disease and TED patients (n=109).
    5. Controls: Healthy donors (n=20).
  • Assays: ELISAs were performed for SPARC, Fibronectin, IGF-1, PDGF-BB, PDL1, FGFs, and FGF23.
  • Correlations: Statistical analysis (Spearman correlation) was used to link serum protein levels with thyroid function tests (FT3, FT4, TSH) and disease activity scores (CAS).

• Immunofluorescence (IHC):

  • Orbital fat sections from TED and non-TED controls were stained for SPARC and $\alpha$-SMA (myofibroblast marker) to validate protein expression and spatial distribution.

3. Key Contributions & Results

A. scRNAseq Findings: Fibroblast Heterogeneity and Signaling

• Cellular Composition: Orbital fat in TED contains a complex network of fibroblasts, endothelial cells, and significant immune infiltration (plasma cells, B cells).
• Thyroid Hormone Sensitivity: Orbital fibroblasts showed high expression of thyroid hormone receptors (THRA, THRB), the T4/T3 transporter (SLC16A2), and the conversion enzyme DIO2. This indicates fibroblasts are highly sensitive to circulating T3 levels.
• TSHR Expression: Contrary to some expectations, TSHR mRNA was low in fibroblasts (though protein stability may explain this), but was enriched in specific lipo-fibroblast subsets (CD34+, FBLN1+).
• Parathyroid Signaling: Fibroblasts expressed PTHR1 and PTHLH, suggesting a paracrine loop involved in fibrosis rather than adipogenesis.
• ECM and Bone Remodeling: Fibroblasts were major producers of ECM proteins, specifically SPARC (osteonectin), COL1A1, BGN, and FN1. They expressed bone-remodeling markers (SPARC, MGP) but lacked canonical osteoblast markers like ALPL, suggesting a fibrotic rather than purely osteogenic phenotype.
• Unique Findings:
  • TPO Expression: Unexpectedly, Thyroid Peroxidase (TPO) was highly expressed by endothelial cells in the orbital fat, not fibroblasts.
  • Fc Receptors: Fibroblasts expressed high levels of FCGRT (neonatal Fc receptor), while immune cells showed heterogeneous Fc receptor profiles.

B. Serum Biomarker Analysis: SPARC as a Key Indicator

• SPARC Elevation: Serum SPARC levels were significantly elevated in all thyroid disease groups compared to healthy controls. Crucially, levels were highest in patients with moderate-to-severe or sight-threatening TED, distinguishing them from those with mild TED or thyroid disease alone.
• Longitudinal Dynamics: In the CIRTED cohort, SPARC levels remained high at 12 weeks but significantly decreased by week 48, correlating with the resolution of active disease (decreased Clinical Activity Score).
• Correlations:
  • FT3: Positive correlation with SPARC in moderate-severe TED.
  • IGF-1: Positive correlation with SPARC across all groups (thyroid disease alone and TED).
  • TSH: Negative correlation with SPARC in moderate-severe TED.
  • TRAb: No significant correlation with SPARC.
• Other Factors: IGF-1 was elevated in thyroid disease but did not further increase in TED. PDGF-BB was elevated in thyroid disease but not consistently in TED.

C. Histological Validation

• Immunofluorescence confirmed heterogeneous expression of SPARC and $\alpha$-SMA in orbital fat.
• SPARC was found in cells surrounding blood vessels and in isolated cells. Some TED samples showed dense fibrotic tissue co-expressing SPARC and $\alpha$-SMA.

4. Significance and Implications

• Novel Biomarker (SPARC): SPARC is identified as a promising, specific biomarker for active TED. Its ability to distinguish moderate-severe TED from mild disease and its decrease during remission make it a valuable tool for monitoring disease activity and treatment response.
• Thyroid Hormone Mechanism: The study provides strong evidence that circulating T3 directly drives orbital fibroblast activity via THRA/THRB and DIO2. This supports the clinical imperative for strict euthyroidism to prevent TED progression, independent of TSHR blockade.
• Pathophysiological Insight: The findings suggest a complex interplay where orbital fibroblasts act as sensors for both thyroid hormones and growth factors (IGF-1, PDGF), driving a fibrotic response (SPARC production) rather than simple adipogenesis.
• Therapeutic Targets: While IGF-1R blockade (teprotumumab) is established, the data highlights PDGF signaling and SPARC-mediated fibrosis as potential additional therapeutic targets.
• Unexpected TPO Localization: The discovery of TPO in orbital endothelial cells suggests a new mechanism for local autoimmunity (interaction with anti-TPO antibodies) that may contribute to TED pathogenesis, particularly in TRAb-negative cases.

Conclusion

This study utilizes single-cell genomics and multi-cohort serum analysis to redefine the molecular landscape of TED. It establishes SPARC as a critical mediator of orbital fibrosis and a robust biomarker for active disease, while highlighting the direct role of thyroid hormone (T3) signaling in driving fibroblast pathology. These findings offer new avenues for biomarker development and therapeutic intervention in Thyroid Eye Disease.